Somewhat Positive Media Coverage Somewhat Unlikely to Impact Voyager Therapeutics (VYGR) Stock Price
News stories about Voyager Therapeutics (NASDAQ:VYGR) have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Voyager Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4338505808105 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Voyager Therapeutics (VYGR) opened at 20.59 on Friday. The firm’s 50-day moving average price is $10.74 and its 200-day moving average price is $10.41. The stock’s market capitalization is $553.93 million. Voyager Therapeutics has a 12 month low of $8.10 and a 12 month high of $22.28.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 66.42% and a negative net margin of 1,603.74%. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. On average, equities research analysts forecast that Voyager Therapeutics will post ($2.84) EPS for the current year.
A number of research firms have recently weighed in on VYGR. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Chardan Capital reaffirmed a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, June 27th. BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $23.43.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Voyager Therapeutics (VYGR) Stock Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-voyager-therapeutics-vygr-stock-price/1599997.html.
In other news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. Following the transaction, the insider now directly owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 27,450 shares of company stock worth $321,769. Insiders own 6.00% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.